Drug Profile
LEO 39652
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator LEO Pharma
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Atopic-dermatitis in Germany (Topical, Cream)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Atopic-dermatitis in United Kingdom (Topical, Cream)
- 01 Jan 2015 LEO Pharma completes a phase I trial in Atopic dermatitis in Germany (NCT02219633)